Table 2.
Comparison of direct (intervention-usual care) or relative (intervention/usual care) changes in clinical measures between treatment groups in the participants who completed the study
| Characteristic | Treatment Effect of Intervention Compared with Usual Carea | ||
|---|---|---|---|
| Difference | 95% Confidence Interval | P Value | |
| Primary outcome measures | |||
| Patient activation total score | 8.7 | 1.9 to 15.5 | 0.01 |
| Patient activation level ≥3b | 4.8 | 1.4 to 16.7 | 0.01 |
| Secondary outcome measures | |||
| Body mass index, kg/m2 | −1.1 | −1.9 to −0.3 | 0.01 |
| BP, mm Hg | |||
| Systolic | −2.9 | −8.6 to 2.8 | 0.32 |
| Diastolic | −4.6 | −12.3 to 3.1 | 0.24 |
| HbA1c, % | −0.7 | −1.3 to −0.2 | 0.01 |
| Serum total protein, g/dl | −0.1 | −0.2 to 0.1 | 0.26 |
| Serum cholesterol, mg/dl | 5.3 | −42.1 to 52.7 | 0.83 |
| Serum triglycerides, mg/dlc | 1.0 | 0.8 to 1.2 | 0.74 |
| Serum HDL cholesterol, mg/dlc | 1.0 | 0.9 to 1.2 | 0.45 |
| Serum LDL cholesterol, mg/dl | 18.5 | −19.3 to 56.3 | 0.34 |
| eGFR, ml/min per 1.73 m2 | 4.7 | −0.5 to 9.9 | 0.08 |
| Urine ACR, mg/gc | 0.6 | 0.3 to 1.2 | 0.15 |
| hsCRP, mg/Lc | 0.3 | 0.2 to 0.5 | <0.001 |
| Morisky scored | −0.4 | −1.1 to 0.4 | 0.34 |
| KDQOL measures | |||
| Symptom/problem list | −2.5 | −7.0 to 2.0 | 0.28 |
| Effects of kidney disease | 0.2 | −2.4 to 2.7 | 0.91 |
| Burden of kidney disease | 8.1 | −0.3 to 16.4 | 0.06 |
| SF-12 physical score | 1.8 | −1.3 to 4.9 | 0.26 |
| SF-12 mental score | 5.0 | 1.8 to 8.2 | 0.002 |
HbA1c, hemoglobin A1c; ACR, albumin-to-creatinine ratio; hsCRP, high-sensitivity C-reactive protein; KDQOL, Kidney Disease Quality of Life Survey; SF-12, Short-Form 12 Health Survey.
Adjusted for the baseline value of each clinical characteristic.
Odds ratio reported for this categorical variable.
Relative differences reported as fold changes. Relative differences greater than one reflect larger positive changes in home-based kidney care than usual care, whereas relative differences less than one reflect larger negative changes in home-based kidney care than usual care.
Use of the Morisky Medication Adherence Scale is protected by United States copyright laws. Permission for use is required. A license agreement is available from Donald E. Morisky, Department of Community Health Sciences, University of California, Los Angeles School of Public Health, 650 Charles E. Young Drive South, Los Angeles, CA 90095–1772.